Mestrallet, G. (2024). Leveraging Tumor Mutation Profiles to Forecast Immune Checkpoint Blockade Resistance in Melanoma, Lung, Head and Neck, Bladder and Renal Cancers. MDPI AG.
Chicago Style (17th ed.) CitationMestrallet, Guillaume. Leveraging Tumor Mutation Profiles to Forecast Immune Checkpoint Blockade Resistance in Melanoma, Lung, Head and Neck, Bladder and Renal Cancers. MDPI AG, 2024.
MLA (9th ed.) CitationMestrallet, Guillaume. Leveraging Tumor Mutation Profiles to Forecast Immune Checkpoint Blockade Resistance in Melanoma, Lung, Head and Neck, Bladder and Renal Cancers. MDPI AG, 2024.
Warning: These citations may not always be 100% accurate.